Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. Feagan BG, et al. Among authors: archambault a. Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84. doi: 10.1111/j.1365-2036.2005.02336.x. Aliment Pharmacol Ther. 2005. PMID: 15709987 Clinical Trial.
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR; CDP571 Crohn's Disease Study Group. Sandborn WJ, et al. Among authors: archambault a. Gastroenterology. 2001 May;120(6):1330-8. doi: 10.1053/gast.2001.24042. Gastroenterology. 2001. PMID: 11313302 Clinical Trial.
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. Hanauer SB, et al. Among authors: archambault a. Can J Gastroenterol. 2007 Dec;21(12):827-34. doi: 10.1155/2007/862917. Can J Gastroenterol. 2007. PMID: 18080055 Free PMC article. Clinical Trial.
Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study.
Veldhuyzen Van Zanten S, Farley A, Marcon N, Lahaie R, Archambault A, Hunt R, Bailey R, Owen D, Spénard J, Stiglick A, Aimola N, Colin P. Veldhuyzen Van Zanten S, et al. Among authors: archambault a. Can J Gastroenterol. 2000 Jul-Aug;14(7):599-602. doi: 10.1155/2000/690307. Can J Gastroenterol. 2000. PMID: 10978947 Clinical Trial.
Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group.
Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, Fedorak R, Bazzoli F, Hentschel E, Mora P, Archimandritis A, Megraud F. Wurzer H, et al. Among authors: archambault a. Aliment Pharmacol Ther. 1997 Oct;11(5):943-52. doi: 10.1046/j.1365-2036.1997.00223.x. Aliment Pharmacol Ther. 1997. PMID: 9354205 Clinical Trial.
Omeprazole and ranitidine in the prevention of relapse in patients with duodenal ulcer disease.
Lauritsen K, Rutgersson K, Bolling E, Brunner G, Eriksson S, Galmiche JP, Walan A, Archambault AP, Gudjónsson H, Bailey RJ, Bianchi Porro G, Frison L, Havu N, Thompson AB. Lauritsen K, et al. Among authors: archambault ap. Can J Gastroenterol. 1999 Dec;13(10):806-13. doi: 10.1155/1999/395876. Can J Gastroenterol. 1999. PMID: 10625320 Clinical Trial.
124 results